학술논문


Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer
Document Type
Article
Source
In European Journal of Cancer July 2023 188:81-89
Subject
Language
ISSN
0959-8049
Abstract
Highlights •This is a multicenter, retrospective and real-world study.•The largest scale data to explore genomic profiles of de novo EGFR CNG.•EGFR CNG had no effect on the efficacy of first-line EGFR-TKI treatment.•NSCLC patients with EGFR CNG had a complex genomic profile.